Kilitch Drugs (India) Limited

NSEI:KILITCH 株式レポート

時価総額:₹5.6b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Kilitch Drugs (India) 将来の成長

Future 基準チェック /06

現在、 Kilitch Drugs (India)の成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長18.0%
収益成長率n/a
将来の株主資本利益率n/a
アナリストカバレッジ

None

最終更新日n/a

今後の成長に関する最新情報

更新なし

Recent updates

Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Jul 23
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Mar 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

Feb 02
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Jan 30
We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Nov 17
Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23
Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Sep 08
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

May 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Jul 06
Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

Apr 08
Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Mar 21
Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 13
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Dec 03
Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Aug 20
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jul 16
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Kilitch Drugs (India) は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NSEI:KILITCH - アナリストの将来予測と過去の財務データ ( )INR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/20241,513126N/AN/AN/A
3/31/20241,544146-66-1N/A
12/31/20231,550146N/AN/AN/A
9/30/20231,532140-262-265N/A
6/30/20231,427117N/AN/AN/A
3/31/20231,396104-1226N/A
12/31/20221,30798N/AN/AN/A
9/30/20221,35285101225N/A
6/30/20221,28183N/AN/AN/A
3/31/20221,14274-2458N/A
12/31/202197652N/AN/AN/A
9/30/2021835634427N/A
6/30/202178062N/AN/AN/A
3/31/20216853794457N/A
12/31/202060217N/AN/AN/A
9/30/20205584-8456N/A
6/30/2020531-3N/AN/AN/A
3/31/20205338-6045N/A
12/31/201960926N/AN/AN/A
9/30/2019534-32N/AN/AN/A
6/30/2019648-3N/AN/AN/A
3/31/201982538-1873N/A
3/31/201851052N/A14N/A
3/31/2017287-89N/A11N/A
3/31/2016210-112N/A172N/A
3/31/2015190-3N/A-76N/A
12/31/2014222-8N/AN/AN/A
9/30/20141998N/AN/AN/A
6/30/2014168-1N/AN/AN/A
3/31/201414912N/A-311N/A
12/31/201315135N/AN/AN/A
9/30/201317828N/AN/AN/A

アナリストによる今後の成長予測

収入対貯蓄率: KILITCHの予測収益成長が 貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: KILITCHの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: KILITCHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: KILITCHの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: KILITCHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: KILITCHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘